Brief: Atea Pharmaceuticals Dosed First Patient In Phase 3 Trial For Covid-19 Treatment

Atea Pharmaceuticals

29/11/2022 12:26

Nov 29 (Reuters) - Atea Pharmaceuticals Inc  AVIR.O :
    * ATEA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN
SUNRISE-3
PHASE 3 REGISTRATIONAL TRIAL OF BEMNIFOSBUVIR, AN
INVESTIGATIONAL ORAL ANTIVIRAL FOR THE TREATMENT OF COVID-19
    * ATEA PHARMACEUTICALS INC - PHASE 3 EVALUATION OF
BEMNIFOSBUVIR
SUPPORTED BY CLINICAL DATA FROM LATE-STAGE MORNINGSKY TRIAL AND
PRIOR STUDIES
    * ATEA PHARMACEUTICALS-STUDY TO EVALUATE BEMNIFOSBUVIR AS
MONOTHERAPY, IN COMBINATION IN NON-HOSPITALIZED PATIENTS AT HIGH
RISK OF DISEASE PROGRESSION

Source text for Eikon:  ID:nGNX5LFgFp 
Further company coverage:  AVIR.O 
 ((Reuters.Briefs@thomsonreuters.com;))